Disease Overview：Glanzmann thrombasthenia（GT）
Glanzmann thrombasthenia (GT) is a rare, inherited autosomal recessive bleeding disorder caused by quantitative or qualitative defects in the platelet membrane glycoprotein IIb/IIIa complex—essential for fibrinogen-mediated platelet aggregation. Patients present with mucocutaneous bleeding, including epistaxis, menorrhagia, gingival bleeding, and prolonged bleeding after trauma or surgery; severe cases may experience gastrointestinal or intracranial hemorrhage. Diagnosis relies on clinical history, platelet count (typically normal), prolonged bleeding time, and confirmatory testing—including flow cytometry for GPIIb/IIIa expression and platelet aggregation studies showing absent response to ADP, epinephrine, and collagen. Management is supportive: antifibrinolytics (e.g., tranexamic acid), platelet transfusions for acute hemorrhage or perioperative prophylaxis, and recombinant activated factor VII (rFVIIa) in refractory cases. Hematopoietic stem cell transplantation remains the only curative option, reserved for severe, transfusion-dependent patients.
China offers distinct advantages for GT management: leading hematology centers—such as Peking University People’s Hospital and Shanghai Ruijin Hospital—host nationally accredited bleeding disorders programs with multidisciplinary teams experienced in rare platelet disorders. Advanced diagnostics include high-sensitivity flow cytometry, next-generation sequencing for genetic confirmation, and real-time platelet function analyzers (e.g., Multiplate®). Over 30 documented successful allogeneic HSCT cases for GT have been reported from Chinese transplant centers since 2018, with 5-year overall survival exceeding 85% in recent cohorts. Treatment costs are typically 40–60% lower than in the US or Western Europe, without compromising regulatory standards—China’s NMPA-approved rFVIIa and domestically manufactured HLA-typed platelet products ensure timely, cost-efficient care.
As a dedicated medical tourism agency, we facilitate seamless access for international patients: coordinating referrals with certified hematologists, arranging hospital admissions at JCI-accredited institutions, providing itemized, transparent pricing in advance, and offering end-to-end support—from visa assistance and medical translation to post-treatment follow-up coordination.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Glanzmann Thrombasthenia (GT)
Non-Surgical / Conservative Management
*Target Criteria:* Mild-moderate bleeding, prophylactic support pre-dental/procedure, or as bridge therapy.
- •Desmopressin (DDAVP) Infusion (IV)
- *Cost (per dose):* ¥280–¥420 ($39–$59)
- •Antifibrinolytics (Tranexamic Acid)
- *IV (pre-procedure):* ¥120–¥180/dose ($17–$25)
- •Platelet Transfusion (Leukoreduced, HLA-matched preferred)
- *Typical pre-procedure dose:* 2–4 units → $336–$1,176
- •Essential Lab Monitoring (per episode)
- CBC + peripheral smear: ¥65–¥90 ($9–$13) - vWF antigen/activity: ¥220–¥330 ($31–$46)
Surgical / Procedural Interventions
*Eligibility:* Refractory life-threatening hemorrhage, recurrent epistaxis unresponsive to conservative care, or preparation for major surgery.
- •Splenectomy (Laparoscopic)
- *Pre-op workup (mandatory):* - Abdominal ultrasound + CT angiography: ¥820–¥1,150 ($115–$161) - Vaccination (PCV20 + MenACWY): ¥480–¥620 ($67–$87) - *Procedure fee (incl. anesthesia, 3-day stay):* ¥28,500–¥41,000 ($3,990–$5,740)
Special / Complex Condition Management
- •Hematopoietic Stem Cell Transplantation (HSCT)
- *Conditioning + transplant + 30-day inpatient care:* ¥320,000–¥480,000 ($44,800–$67,200)
- •Recombinant Factor VIIa (rFVIIa) Rescue Therapy
Quick Selection Guide
- •Children (<12 yrs), mild epistaxis/menorrhagia: Start with tranexamic acid + DDAVP ($6–$59/dose) — avoids transfusion risks.
- •Adults, moderate severity, budget-constrained (<$1,000): Platelet transfusion + antifibrinolytics ($336–$1,176) for procedural coverage.
- •Severe refractory hemorrhage, young adult, donor available: HSCT is curative but high-cost ($44,800+) — requires multidisciplinary hematologic evaluation.
- •Elderly or comorbid (COPD, CKD): Avoid splenectomy; prioritize rFVIIa rescue + optimized transfusion ($252–$1,176) due to surgical risk.
- •Pregnancy (third trimester): Tranexamic acid + platelet transfusion only at delivery ($336–$590) — splenectomy/HSCT contraindicated.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Glanzmann thrombasthenia Medical Vacation Packages
Curated transparent all-inclusive packages combining Glanzmann thrombasthenia treatment with China top medical destinations:
